心房細動治療薬市場：製品タイプ、用途、エンドユーザー、地域別、2024年～2031年

心房細動治療薬市場の評価、2024年～2031年

増加する人口、特に高齢人口における肥満や高血圧などのライフスタイルに関連した危険因子の治療率の上昇は、早期発見と治療の需要を強化し、心房細動薬市場に大きな機会を生み出しています。Verified Market Researchのアナリストによると、心房細動治療薬市場は2023年に147億8,000万米ドルの評価を下回り、予測期間中に199億1,000万米ドルの評価に達すると推定されます。

抗不整脈薬、抗凝固薬、レートコントロール医薬品の開発など、新しい治療技術に焦点を当てた継続的な研究努力は、心房細動薬市場の拡大をさらに増加させ、2024年から2031年までCAGR 3.8％で市場が成長することを可能にしています。

心房細動治療薬市場：定義/概要

心房細動治療薬は、心臓の上室（心房）で発生する不規則で速い心拍を特徴とする一般的な心臓リズム疾患である心房細動の管理と治療を特に目的とした薬剤です。これらの薬は心房細動の治療において、正常な心臓のリズム（洞調律）を回復させ、心拍数を管理し、血栓や脳卒中のリスクを下げるなど、さまざまな機能を果たします。

さらに、抗不整脈薬は規則正しい心拍を回復させるために処方されるのが一般的であるが、心拍数管理薬は心拍数を正常範囲内に保とうとするものです。また、心房細動の人は不整脈のために血栓のリスクが高いので、血栓の開発を防ぎ、脳卒中のリスクを下げるために抗凝固薬が処方されることが多いです。

慢性疾患の高い有病率は心房細動治療薬市場にどのような影響を与えるか？

世界中で心房細動の有病率が高まっていることは、市場の重要な促進要因です。心房細動は重篤な不整脈の中で最も頻度が高く、世界中で数百万人が罹患しており、新たな治療法の必要性が高まっています。心房細動の罹患率は加齢とともに上昇するため、人口の高齢化が進んでおり、高血圧、糖尿病、肥満などの基礎疾患の罹患率も上昇しています。

特に先進経済諸国と新興経済諸国における世界の医療支出の増加は、心房細動治療薬市場の拡大に寄与しています。ヘルスケアが質の高い治療とアウトカムを優先する中、心房細動のような慢性疾患の効果的な管理がより重視されるようになり、革新的な治療法の使用により患者の予後を改善し、長期的な医療費を削減することができます。

さらに、心房細動の早期発見と治療は、脳卒中や心不全などの結果を予防する上でますます重要になってきています。心臓のリズムをモニターして異常を特定できるウェアラブル技術やモバイルヘルスアプリの普及による早期発見も、市場拡大を後押ししています。こうした取り組みによって心房細動と診断される人の数が増え、薬物療法を必要とする患者層が拡大します。

心房細動治療薬の副作用は市場に何をもたらすか？

心房細動の治療に使用される多くの薬剤、特に抗凝固薬には、出血の問題など重大な副作用が伴う。このような安全性への懸念から、特定の患者への特定の薬剤の使用が制限され、ヘルスケア従事者や患者が心房細動を薬理学的に管理することに躊躇し、市場の成長を制限しています。

心房細動市場において重要な薬剤の特許が切れるとジェネリック医薬品の競争が起こり、先発医薬品を製造していた製薬会社の収益は大幅に減少します。ジェネリック医薬品は医薬品をより安価にする一方で、技術革新や新薬研究への投資意欲を減退させるという課題を市場に突きつけています。

さらに、心房細動が世界的に流行しているにもかかわらず、多くの新興国では、高額な費用、医療インフラの不足、ヘルスケア提供者や患者の認識不足のために、最新の抗凝固薬を含む最新の治療オプションへのアクセスが依然として限られています。この困難は、社会経済的理由やヘルスケアシステムの違いによってさらに悪化し、これらの地域における心房細動治療薬市場の拡大を妨げています。

目次

第1章 世界の心房細動治療薬市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 心房細動治療薬の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル

第5章 心房細動治療薬の世界市場：製品別

• 概要
• 抗不整脈薬
• 抗凝固薬
  • ビタミンK拮抗薬
  • 新規経口抗凝固薬

第6章 心房細動治療薬の世界市場：タイプ別

• 概要
• 発作性
• 持続性
• 永続性

第7章 心房細動治療薬の世界市場：用途別

• 概要
• リズムコントロール（洞調律維持）
• レートコントロール（心拍数調節）

第8章 心房細動治療薬の世界市場：エンドユーザー別

• 概要
• 病院
• 心臓センター
• 外来手術センター

第9章 心房細動治療薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州・アフリカ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 心房細動治療薬の世界市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Abbott Laboratories
• Bristol-Myers Squibb
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Merck & Co., Inc.
• Daiichi Sankyo Company, Limited
• Boehringer Ingelheim GmbH

第12章 付録

• 関連調査

Atrial Fibrillation Drugs Market Valuation - 2024-2031

Rising rates of lifestyle-related risk factors such as obesity and hypertension among the growing population, especially geriatric populace, is bolstering the demand for early detection and treatment, creating immense opportunities for Atrial Fibrillation Drugs Market. According to the analyst from Verified Market Research, the Atrial Fibrillation Drugs Market is estimated to reach a valuation of USD 19.91 Billion over the forecast subjugating aroundUSD 14.78 Billion valued in 2023.

Ongoing research efforts focusing on novel therapeutic techniques, such as the development of anti-arrhythmic medicines, anticoagulants, and rate control pharmaceuticals, are further increasing Atrial Fibrillation Drugs Market expansion and enabling the market to grow at aCAGR of 3.8% from 2024 to 2031.

Atrial Fibrillation Drugs Market: Definition/ Overview

Atrial fibrillation drugs are medications that are specifically intended to manage and treat atrial fibrillation, a common heart rhythm disease characterized by irregular and fast heartbeats that originate in the heart's upper chambers (atria). These medications perform a variety of functions in the treatment of atrial fibrillation, including restoring normal heart rhythm (sinus rhythm), managing heart rate, and lowering the risk of blood clots and stroke.

Furthermore, anti-arrhythmic drugs are commonly prescribed to assist restore a regular heart rhythm, whereas rate control medications try to keep the heart rate within normal limits. Also, anticoagulant drugs are often prescribed to prevent blood clot development and lower the risk of stroke, as people with atrial fibrillation have a higher risk of blood clots due to their irregular heartbeat.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will High Prevalence of Chronic Illnesses Affect the Atrial Fibrillation Drugs Market?

The growing prevalence of atrial fibrillation around the world is a significant driver of the market. Atrial fibrillation is the most frequent type of severe arrhythmia, affecting millions of people globally, increasing the need for new treatment alternatives. Ageing populations, as AFib incidence rises with age, as well as rising rates of underlying diseases such as hypertension, diabetes, and obesity, all contribute to rising prevalence.

Increased global healthcare spending, particularly in developed and emerging economies, contributes to the expansion of the Atrial Fibrillation Drugs Market. With healthcare systems prioritizing quality care and outcomes, there is a greater emphasis on the effective management of chronic illnesses such as atrial fibrillation This involves the use of innovative treatment alternatives, which can improve patient outcomes and lower long-term healthcare expenditures.

Furthermore, early identification and treatment of atrial fibrillation are becoming increasingly important in preventing consequences such as stroke and heart failure. Early detection through the widespread use of wearable technology and mobile health apps that can monitor cardiac rhythms and identify anomalies also helps to drive market expansion. These initiatives increase the number of people diagnosed with atrial fibrillation, which broadens the patient pool that requires drug therapy.

What will Side Effects of Atrial Fibrillation Drugs have on the Market?

Many drugs used to treat atrial fibrillation, particularly anticoagulants, are associated with substantial side effects, such as bleeding problems. These safety concerns limit the use of specific medications in particular patients cause healthcare practitioners and patients to be hesitant about managing atrial fibrillation pharmacologically, and limiting market growth.

The expiration of patents for important medications in the atrial fibrillation market allows for generic competition, substantially decreasing revenue for pharmaceutical companies that produced the original branded drugs. While generics make drugs more affordable, they also pose a challenge to the market by reducing incentives for innovation and investment in new medication research.

Furthermore, despite the global prevalence of atrial fibrillation, many emerging economies still have limited access to modern treatment options, including the most recent anticoagulants, due to high costs, a lack of healthcare infrastructure, and a lack of awareness among healthcare providers and patients. This difficulty is exacerbated by socioeconomic reasons and differences in healthcare systems, which impede the expansion of the atrial fibrillation medication market in these locations.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for the Anticoagulant segment?

According to VMR analysis, the anticoagulant drugs segment is estimated to hold the largest market share during the forecast period. The global growth in atrial fibrillation prevalence has led to an increase in the demand for better stroke prevention methods. Anticoagulant medications, particularly NOACs, are the cornerstone of stroke prevention in atrial fibrillation patients, which contributes to their market dominance. The emphasis on lowering the risk of stroke in atrial fibrillation patients with appropriate anticoagulant medication contributes to the segment's sustained expansion and dominance.

Novel Oral Anticoagulants (NOACs) have been proven to be as effective as or more effective than Vitamin K Antagonists (VKAs) such as warfarin, with a better safety profile, particularly in terms of lowering the risk of significant bleeding problems. NOACs also have less food-drug interactions than VKAs, making them a more convenient choice for patients. This increased efficacy and safety profile has resulted in a high preference for NOACs among healthcare providers and patients, contributing to the anticoagulant drug segment's dominance.

Furthermore, clinical recommendations from top cardiology and thrombosis associations throughout the world increasingly advocate NOACs over VKAs for the majority of AFib patients due to their favorable benefit-risk profile. These guidelines have an impact on prescribing practices and have played a crucial role in the broad adoption of NOAC. The robust endorsement by clinical guidelines assures that NOACs continue their leading position in the anticoagulant drug market.

What are the Potential Factors for the Dominance of Paroxysmal Type in the Market?

The paroxysmal segment is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. Paroxysmal Atrial Fibrillation, which is characterized by the abrupt start of irregular heartbeats that stop within seven days (typically resolving within 24 hours), is common since it is frequently the first phase of atrial fibrillation in many people. Drugs aimed at this segment are in more demand because of their episodic character, which often makes it the first kind of atrial fibrillation to be recognized and treated.

Paroxysmal atrial fibrillation is generally treated with a combination of medicines, ranging from anticoagulants to prevent strokes to antiarrhythmic drugs to regulate rhythm. This variety of treatment alternatives can help the segment get a greater market share because it includes a wide range of pharmaceuticals that can be adapted to particular patient needs, as well as newer and more advanced pharmacological breakthroughs.

Furthermore, effectively managing paroxysmal atrial fibrillation can stop or slow the development of more chronic and persistent forms of the condition, which are more difficult to treat and have a higher risk of problems. This therapeutic potential supports a high emphasis on early and effective treatment techniques, including medication therapies, which contributes to the segment's dominance in the Atrial Fibrillation Drugs Market.

Country/Region-wise Acumens

What are the Factors that Contribute to North America's Competitive Edge in the Market?

According to VMR analyst, North America is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. North America, particularly the United States, has a high frequency of cardiovascular disorders, including atrial fibrillation, which is caused by variables such as ageing populations, lifestyle choices, and obesity. This results in a large patient pool requiring atrial fibrillation treatment, which fuels demand for atrial fibrillation drugs.

The region has advanced healthcare systems that provide extensive access to cutting-edge medical technology and treatments. This infrastructure promotes early diagnosis, treatment innovation, and successful management of atrial fibrillation, resulting in higher acceptance rates of innovative atrial fibrillation medications than other locations.

Furthermore, North America is a pharmaceutical research and development hotspot, with a significant emphasis on innovative drug therapies. The presence of major pharmaceutical companies, as well as significant investment in R&D activities, help to accelerate the release of novel and effective atrial fibrillation medications, boosting market expansion in the region.

Will Flourishing Healthcare Infrastructure in Asia Pacific Boom Atrial Fibrillation Drugs Market?

Asia Pacific region is estimated to exhibit the highest growth in the market during the forecast period. Asia Pacific is experiencing a substantial demographic shift, with increasing ageing populations, particularly in Japan and China. Older age is a significant risk factor for atrial fibrillation, resulting in an increasing patient population in need of atrial fibrillation treatments and driving demand for atrial fibrillation medications in the region.

This region is experiencing significant advances in healthcare infrastructure and increased healthcare spending. Countries are investing in better healthcare infrastructure and treatment access, making modern atrial fibrillation medications more accessible to the general public, hence driving market expansion.

Furthermore, in the Asia-Pacific region, there is growing awareness of atrial fibrillation and associated complications. When combined with increased healthcare access and insurance coverage, this leads to higher diagnostic rates and treatment uptake, driving the expansion of the Atrial Fibrillation Drugs Market.

Competitive Landscape

The competitive landscape of the Atrial Fibrillation Drugs Market is marked by fierce competition among several players vying for a significant market share. In addition, market participants frequently pursue strategic partnerships, collaborations, and acquisitions to boost their market position and broaden their product ranges.

Some of the prominent players operating in the Atrial Fibrillation Drugs Market include:

Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc., Novartis AG, Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Medtronic plc, Shionogi & Co., Ltd., Astellas Pharma Inc., Meda Pharmaceuticals, and Cardionomic Therapeutics Inc.

Latest Developments

In October 2023, Bristol-Myers Squibb announced favorable findings from the Phase 3 PEACH-AF trial. The experiment assessed the efficacy and safety of the investigational medication, lixisenatide, in preventing stroke in individuals with AF.

In September 2023, Pfizer Inc. announced a collaboration with Apple to create a new wearable device that can detect and monitor AF via a person's smartphone.

In April 2023, Johnson & Johnson presented results at the American College of Cardiology meeting that demonstrated the long-term safety and efficacy of their medicine, Edoxaban, in avoiding stroke in patients with AF.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ATRIAL FIBRILLATION DRUGS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antiarrhythmic Drug
• 5.3 Anticoagulant Drugs
  • 5.3.1 Vitamin K Antagonists
  • 5.3.2 Novel Oral Anticoagulants

6 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY TYPE

• 6.1 Overview
• 6.2 Paroxysmal
• 6.3 Persistent
• 6.4 Permanent

7 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Heart Rhythm Control
• 7.3 Heart Rate Control

8 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY END USER

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Cardiac Centers
• 8.4 Ambulatory Surgical Centers

9 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe & Africa
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Bristol-Myers Squibb
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Johnson & Johnson
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Pfizer Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Novartis AG
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 F. Hoffmann-La Roche Ltd
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Sanofi S.A.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Merck & Co., Inc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11. 9 Daiichi Sankyo Company, Limited
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Boehringer Ingelheim GmbH
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research